TLS Atlas: Turning Tumor Immune Architecture into a Clinical Biomarker: Science | May 2026

• Tertiary lymphoid structures are local immune hubs within tumors, but this study shows that their mere presence is not enough; their maturation, location, and cellular organization determine biological and clinical relevance.

• This pan-cancer study analyzed TLS biology across 12 cancer types, combining spatial transcriptomics with artificial intelligence applied to routine H&E pathology slides.

• TLSs were classified along a maturation spectrum: early TLS, primary follicle–like TLS, and secondary follicle–like TLS, reflecting increasing immune organization.

• Mature TLSs showed coordinated immune architecture, including B-cell and T-cell zoning, follicular dendritic cell networks, chemokine signaling, and interferon-related immune activation.

• The spatial position of TLSs mattered. Intratumoral, peritumoral, and distal TLSs were associated with different immune and tumor signaling patterns.

• Tumor regions close to intratumoral TLSs showed stronger antigen presentation and immune activation signatures, including interferon and MHC class II pathways.

• Tumor regions farther from TLSs showed relatively higher proliferative and invasive programs, including MYC signaling, cell-cycle activity, and epithelial–mesenchymal transition.

• The authors developed an AI-based model capable of detecting and phenotyping TLSs directly from standard H&E whole-slide images, making the approach potentially scalable for routine pathology.

• A maturation-aware TLS composite score performed better than simple “TLS present or absent” assessment for patient stratification across cancer and treatment settings.

• This work suggests that TLS profiling may become a future immuno-oncology biomarker, helping predict prognosis, treatment response, and possibly guide trial design.

• The clinical implication is important: future cancer immunotherapy decisions may depend not only on tumor genomics or PD-L1 expression, but also on the spatial immune architecture of the tumor microenvironment.

• Prospective validation is still needed before TLS scoring can be used routinely in clinical practice.

Bottom line: This study transforms TLSs from a descriptive pathology feature into a measurable, AI-enabled spatial biomarker with potential relevance for immunotherapy selection and cancer prognosis.